Healthcare giant Gilead Sciences, Inc. (NASDAQ:GILD) is gearing up for another quarterly report after the closing bell on Wednesday. This time, the report will cover results from the second quarter of fiscal 2017.
Ahead of the print, Mizuho analyst Salim Syed provides a quick take on what to look for: “Namely, investors will look for any updates from the company on the HCV franchise. We will look for any updated thoughts on trends and magnitude of decline given we are now into the second half of 2017. Note, however, HCV scripts for 2Q17 looks relatively flattish vs 1Q17. Recall, the company has launched two DTC campaigns, and we will look for any information on the impact those have had on prescription trends.”
Furthermore, “Investors will also look for potential updates on GILD’s 2017 full year guidance. Recall that on the 1Q’17 call, management reiterated guidance and the company noted that the “year is progressing consistent with expectations.”
Finally, “We will be looking for updated thoughts on BD. Recall, Alessandro Riva from Novartis was hired as the Hematology and Oncology therapeutic area head so more activity in this area has been expected by investors. On the pipeline, we will be looking for updates on the progress of the NASH candidates and filgotinib for inflammation. We will also look for any color on the potential use of a priority voucher for the Bictegravir/F/TAF NDA.”
Syed rates GILD stock a Buy with a price target of $77, which represents a slight upside potential from current levels. (To watch Syed’s track record, click here)
Out of the 13 analysts polled in the past 3 months, 10 rate Gilead stock a Buy, while 3 rate the stock a Hold. With a return potential of 11%, the stock’s consensus target price stands at $82.